APA (7th ed.) Citation

Chladek, M., Hunsche, E., Hudgens, S., Brown, B., Fallick, M., dePaauw-Holt, S., . . . Ross, A. (2022). PCR172 Development of a Novel Patient-Reported Outcome (PRO) Measure to Assess Hormonal-Based Treatment Symptoms and Their Impacts in Patients with Prostate Cancer. Value in Health, 25(7), S573. https://doi.org/10.1016/j.jval.2022.04.1515

Chicago Style (17th ed.) Citation

Chladek, M., E. Hunsche, S. Hudgens, B. Brown, M. Fallick, S. dePaauw-Holt, K. Cox, and A. Ross. "PCR172 Development of a Novel Patient-Reported Outcome (PRO) Measure to Assess Hormonal-Based Treatment Symptoms and Their Impacts in Patients with Prostate Cancer." Value in Health 25, no. 7 (2022): S573. https://doi.org/10.1016/j.jval.2022.04.1515.

MLA (9th ed.) Citation

Chladek, M., et al. "PCR172 Development of a Novel Patient-Reported Outcome (PRO) Measure to Assess Hormonal-Based Treatment Symptoms and Their Impacts in Patients with Prostate Cancer." Value in Health, vol. 25, no. 7, 2022, p. S573, https://doi.org/10.1016/j.jval.2022.04.1515.